New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
05:47 EDTAGIOAgios Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Agios Pharmaceuticals to Overweight citing a declined risk profile following the company's "robust" interim phase 1 data on AG-221. The firm raised its price target for shares to $55 from $40.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
07:32 EDTAGIOAgios Pharmaceuticals appoints Steve Hoerter as Chief Commercial Officer
Agios Pharmaceuticals announced the appointment of Steve Hoerter to the newly created position of chief commercial officer, effective February 16. Hoerter has more than 20 years of global pharmaceutical and biotechnology experience, most recently having served as executive vice president and chief commercial officer at Clovis Oncology, Inc. as well as previous senior commercial roles at Genentech and Roche.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use